Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.
Qpinch’re committed to bringing their innovative chemical heat transformer to your plant and to helping your business save on energy bills while reducing your environmental footprint.
EclecticIQ specializes in threat intelligence and cybersecurity solutions, offering technology and services that enhance the defense against cyber threats. The company develops platforms that integrate and analyze intelligence data from various sources, including open and commercial suppliers, as well as industry partnerships. This integration allows organizations to improve their detection, prevention, and response capabilities against adversaries. By embedding intelligence into cybersecurity frameworks, EclecticIQ aims to empower enterprises to effectively combat evolving cyber threats.
Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
HalioDx is a company focused on designing and developing diagnostic tests in oncology that assess the immune contexture of cancers. It offers a range of immunologic scoring tests that investigate the immune response within the tumor environment. Utilizing a proprietary set of immune biomarkers and advanced image analysis technologies, HalioDx's tests accurately measure the immune reaction in and around tumors. This information helps clinicians evaluate the severity of a patient's disease and predict their response to treatment, ultimately aiding in personalized patient care.
Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.
Cartagenia delivers expert systems and services to enable genetic labs and clinicians to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high quality genetic interpretation and counseling.
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.
Anteryon, based in Eindhoven, the Netherlands, is a manufacturer specializing in optical precision elements and miniature optical modules. Originally a business unit of Philips, it became an independent entity in 2006. The company focuses on providing standard and customized optical components, utilizing patented replication and opto-mechanical assembly technologies, alongside expertise in coatings, lithography, and precision glass. Anteryon serves diverse markets, including industrial, imaging and display, and data and telecom, delivering solutions that encompass lenses, laser modules, fiber collimators, and integrated lens stacks. Its products are integral to various applications, such as automotive safety systems, optical data storage, and multiview displays. Notably, Anteryon's innovations include WaferOptics® technology, facilitating advanced stacking techniques at the wafer level. The company is well-positioned for growth in the mobile phone camera module sector, catering to an expanding global demand for camera-enabled devices.
Active Circle develops and markets an innovative software-based solution that addresses the need for storing, preserving, and managing large volumes of digital content.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
iNEWiT, an engineering company, engages in identifying, designing, and creating applications and devices for the mobile market. It provides mobile video communication applications; wireless communication technologies, ranging from GPRS/EDGE, over 3G, HSDPA/HSUPA to WiFi, and WiMAX and satellite networks; and plug and play products for the business-to-consumer markets. The company was founded in 2005 and is based in Mechelen, Belgium
Certess is the only electronic design automation (EDA) company providing functional qualification products for companies that create and integrate complex design blocks or intellectual property (IP). Most advanced functional verification teams currently use a combination of techniques to gain visibility into the question of verification quality only to constantly fall short of the ability to truly qualify designs. Although verification engineers have dedicated tools and methodologies for verification quality improvement, functional logic errors still remain the largest causes of chip respins. They provide design and verification engineers with an objective way to evaluate and improve the completeness of the verification environment, resulting in a shorter and more predictable process to integrate SoC designs and ensure high quality designs. The company was incorporated in 2005 and was based in Campbell, California. In March 2009, Certess was acquired by SpringSoft, LLC.
TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.
MAPPER Lithography B.V. develops lithography machines for the chip industry. The company was founded in 2000 and is based in Delft, the Netherlands.
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
Plastic Logic Ltd specializes in the development and manufacturing of plastic electronics, particularly flexible displays. The company produces both color and monochrome electrophoretic displays, which are utilized in a variety of applications including smartphones, e-readers, tablets, signage, wristwatches, and automotive displays. With a focus on lightweight, shatterproof, and energy-efficient technology, Plastic Logic's products offer significant advantages over traditional screens. The company's manufacturing capabilities are centered in Dresden, Germany, where it operates a pioneering facility dedicated to organic electronics. It serves a diverse clientele, including OEMs, system integrators, and device manufacturers in multiple countries, including the United Kingdom, Germany, and Russia. Additionally, Plastic Logic collaborates with third-party companies through an open pilot line, providing expertise in the industrialization of flexible electronics. Founded in 2000 and based in Cambridge, Plastic Logic continues to innovate in the field of flexible display technology.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Clear2Pay is a payments technology company that specializes in electronic payment services. Its Open Payment Framework (OPF) allows financial institutions to enhance their internal payments processing efficiencies while offering clients faster payment services enriched with detailed information. This framework operates on a Service-Oriented Architecture (SOA), enabling banks to utilize a centralized payments engine with a library of reusable business services applicable across all payment types. By integrating new service models with existing infrastructures, Clear2Pay helps banks protect their previous investments and transition to a more modern and efficient payments environment. Additionally, the company provides a Software Development Kit and a Bank Payment Hub, which facilitates customer interaction, order management, and payment execution, along with services for dispute and exception processing.
Gemidis is a spin-off company from Ghent University (Belgium) and IMEC (Belgium) and was officially founded in August 2004. Gemidis develops, produces and sells LCOS imagers and driver electronics for both consumer and professional markets.
Welcome Real Time S.A. is a company that specializes in electronic payment software and services, primarily for financial institutions, payment networks, and retailers. Established in 1996 and headquartered in Aix-en-Provence, France, it offers a variety of solutions including credit and debit card acceptance, and integrated value-added services. Key products include XLS Server, which enhances EMV capabilities for payment processing systems; XLS POS, a toolkit for developing payment applications; and XLS Card, which supports card personalization and issuance. Additionally, Welcome Real Time provides CardCare for cardholder services and MerchantCare for merchant activity reporting. With research and development facilities in multiple global locations, the company focuses on creating point-of-sale customer loyalty programs and smart payment device software, along with offering maintenance and marketing consulting services.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. The company is advancing several oncology programs, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently in Phase I trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia. CYC140, a polo-like kinase inhibitor, is also in Phase I trials for advanced leukemias. Additionally, sapacitabine, an oral nucleoside analogue prodrug, is being evaluated in a Phase 1/2 combination study with seliciclib, another CDK inhibitor, for patients with BRCA mutations. Cyclacel's pipeline includes collaborations with notable institutions, such as the University of Texas MD Anderson Cancer Center, to assess the safety and efficacy of its treatments in hematological malignancies. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.